Maravai (MRVI) Q1 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool Sun, May 10, 2026 at 3:35 AM GMT+7 26 min read MRVI Image source: The Motley Fool. Chief Financial Officer — Rajesh Asarpota Chief Scientific Officer — Chanfeng Zhao Need a quote from a Motley Fool analyst? Email pr@fool.com Debra Hart: Good afternoon, everyone. Thanks for joining us for our first quarter 2026 earnings call. The press release and slides accompanying today s call are posted on our website and available at investors.maravai.com. As you can see from the agenda on Slide 2, our CEO, Bernd Brust, will provide a business update and our CFO, Rajesh Asarpota, will review our financial results. Chanfeng Zhao, our Chief Scientific Officer, will join us for the Q&A session. Management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today s call. It is possible that actual results could differ from expectations. We refer you to Slide 3 for details on forward-looking statements and our use of non-GAAP financial measures. The press release provides reconciliations to the most directly comparable GAAP measures and we also post reconciling schedules to our investor website. Please also refer to Maravai LifeSciences Holdings, Inc.’s SEC filings for additional information on the risks and uncertainties that may impact our operating results, performance, and financial condition. Now I will turn the call over to Bernd. Good afternoon, and thank you for joining us. Bernd Brust: We are very pleased with our first quarter performance, which represents a strong start to 2026 and builds on the momentum we exited with last year. The quarter results reflect solid execution across the business and reinforce our confidence in the trajectory we outlined on our call in February. Turning to Slide 5, we delivered total Q1 revenue of $65.8 million. That is 41% year-over-year growth, and 10% year-over-year growth in our base business when you exclude COVID-related CleanCap revenue. This performance was driven by improved TriLink demand, steady contribution from Cygnus, and continued progress against our strategic priorities. TriLink revenue grew 65% year over year, with base business growth of 15%, supported by strong demand in both GMP and discovery consumables. At Cygnus, revenue grew a little more than 1% year over year. We saw solid underlying momentum with high single-digit growth in North America and low single-digit growth in EMEA, reinforcing our confidence in the positioning of the business. This was partially offset by lower contribution from China due to distributor ordering timing. From a profitability standpoint, we delivered adjusted gross margin of 65.3% and adjusted EBITDA of $20.3 million. These results reflect the benefit of higher revenue, favorable product and customer mix, and the cost disciplines we have implemented across the organization. We also generated $4.2 million of positive free cash flow in the quarter, which is the first time the company has been cash flow positive since 2024. We see this as another clear indication that the structural improvements we have made are taking hold. Given our strong start to the year and improved visibility into the balance of 2026, we are increasing the range for our full-year revenue expectations and substantially raising our EBITDA guidance. Raj will walk through that in more detail shortly. Now let us turn to Slide 6 for an update on our performance against our three strategic pillars: commercial execution, operational excellence, and, of course, innovation. Starting with commercial execution, we are seeing strong momentum across the business. Our increased focus on customer engagement is translating into better forecasting, improved visibility, and stronger order conversion. We are securing more annual and multi-quarter purchase orders, which is improving the stability and predictability of our revenue base. This is a meaningful shift from where we were a year ago and reflects the effectiveness of the changes we have made in our commercial go-to-market approach. That said, our business has a disproportionate number of large orders that can result in quarter-over-quarter performance variation. Large orders tend to align with customer program progression, and as a result, revenue can vary between periods. What gives us confidence is not the timing of any single order, but the strength and continued expansion of the underlying opportunity funnel. Within TriLink, our portfolio now spans enabling technologies such as CleanCap and Motto, along with custom and catalog mRNA enzymes, oligonucleotides including guide RNAs, and a broad range of nucleotide chemistries, including NTPs. This breadth allows us to participate more deeply across the mRNA and gene therapy workflows. We also recently launched all-in-one IVT kits, which simplify the production of capped RNA and provide early-stage researchers with easier access to our platform. At TriLink, our model continues to work

Maravai (MRVI) Q1 2026 Earnings Transcript

Key takeaways

Also covered by

Maravai (MRVI) Q1 2026 Earnings Transcript

Key takeaways

Also covered by

More in business